Larimar Therapeutics (NASDAQ:LRMR) Stock: Insider Michael Celano Acquires 18,460 Shares

Key Points

• CFO Michael Celano bought 18,460 Larimar shares at an average price of $2.71, spending about $50,027. The purchase increased his direct ownership by 8.55% to 234,245 shares.
• LRMR shares fell 3 cents to $2.70 on Thursday. The stock’s one-year range is $1.91 to $6.42.
• Analysts have a consensus “Buy” rating and an average price target of $10.33, based on two Strong Buy, six Buy, and one Sell ratings.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) CFO Michael Celano purchased 18,460 shares of the stock in a transaction dated Wednesday, November 11th. The shares were purchased at an average cost of $2.71 per share, for a total transaction of $50,026.60. Following the completion of the acquisition, the chief financial officer directly owned 234,245 shares in the company, valued at approximately $634,803.95. This trade represents a 8.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Larimar Therapeutics Stock Performance

Shares of LRMR stock traded down $0.03 on Thursday, reaching $2.70. The stock had a trading volume of 1,190,176 shares, compared to its average volume of 2,378,292. Larimar Therapeutics, Inc. has a 1 year low of $1.91 and a 1 year high of $6.42. The stock has a market cap of $280.48 million, a P/E ratio of -1.38 and a beta of 0.73. The company has a 50 day simple moving average of $2.97 and a 200 day simple moving average of $3.77.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC bought a new position in Larimar Therapeutics in the 2nd quarter worth $27,000. Pallas Capital Advisors LLC bought a new stake in Larimar Therapeutics during the second quarter valued at about $31,000. HB Wealth Management LLC bought a new stake in Larimar Therapeutics during the second quarter valued at about $49,000. The Manufacturers Life Insurance Company bought a new stake in Larimar Therapeutics during the second quarter valued at about $60,000. Finally, Walleye Trading LLC purchased a new position in shares of Larimar Therapeutics in the second quarter valued at about $61,000. Institutional investors own 91.92% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on LRMR shares. Weiss Ratings restated a "sell (d-)" rating on shares of Larimar Therapeutics in a research note on Thursday, October 15th. Wedbush reiterated an "outperform" rating on shares of Larimar Therapeutics in a research note on Tuesday. Finally, Leerink Partners began coverage on shares of Larimar Therapeutics in a report on Monday, September 14th. They issued an "outperform" rating and a $13.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $10.33.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.